Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Exelixis Inc (EXEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 106.00 thousand shares for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-02-10
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2026 was 106.00K shares, a 84.06% decline from fiscal 2025.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 665.00K shares, a 3.76% decline from fiscal 2023.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 691.00K shares, a 8.82% increase from fiscal 2022.
- Exelixis Inc share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 635.00K shares, a 16.51% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|
| 2026-01-02 | 106.00K shares 10-K · filed 2026-02-10 |
| 2025-01-03 | 665.00K shares 10-K · filed 2025-02-11 |
| 2023-12-29 | 691.00K shares 10-K · filed 2024-02-06 |
| 2022-12-30 | 635.00K shares 10-K · filed 2023-02-07 |
| 2021-12-31 | 545.00K shares 10-K · filed 2022-02-18 |
| 2021-01-01 | 318.00K shares 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |